Nazarin Yana Nuna Hanyoyin Halitta Na Nuna Babu Rashin Ƙari na Ciwon Kankara
Ciwon ƙwayar cutar kankara
Bincike ya nuna babu wani shaida a yau cewa farfadowa na maganin arthritis yana kara yawan ciwon nono, musamman magunguna mafi mahimmanci. Ƙungiyar Bayar da Bayani na Rukunin Rheumatic (NDB) na kasa ta gabatar da bincike a taron Turai na Rheumatology na shekara ta Turai da aka yi ta Turai game da Rheumatism (EULAR) a shekara ta 2005.
Sabbin magungunan, wanda aka sani da magungunan maganin halitta ko kwayoyin halitta, sun haɗa da kwayoyi:
Wadannan magunguna suna da amfani na musamman saboda sababbin jiyya sun kara haɗarin wasu cututtuka a marasa lafiya na rheumatoid arthritis (RA). Wani bincike na NDB na baya ya sami wata ƙungiya tsakanin ilimin halittu da wadanda basu da ciwon nama ba.
Binciken na bincike ya nuna cewa saboda kwayoyi sun kasance a kasuwa kawai na 'yan shekarun nan, haɗarin rashin lafiya ga farfadowa na iya zama gajere don kammalawa mai zurfi kuma cewa kara nazarin zai zama dole.
Mene ne Ma'anar Amfani da Halitta na Halitta?
Sakamakon gyaran maganganu na kwayoyin halitta suna daga cikin sababbin kwayoyi da ake amfani dasu don magance cututtuka na rheumatoid. Halittun halittu su ne magunguna waɗanda suke dogara ne akan mahadi wadanda aka yi ta kwayoyin halitta. Maganin ilimin halittu yana amfani da maganganu masu dacewa da kwayoyin halitta don ƙarfafawa ko mayar da damar da tsarin rigakafi ya yi don yaki da cutar da / ko kamuwa da cuta. Binciken halittu na iya hada da:
- interferon
- interleukin-2
- daban-daban iri-iri-stimulating dalilai
Magungunan Enbrel, Remicade, da Humira, sunyi tasiri ga TNF-alpha. TNF-alpha yana daya daga cikin magungunan cytokine mafi muhimmanci da ke cikin cututtukan arthritis na rheumatoid ta hanyar rikici a cikin rikice-rikice na halayen ƙwayar cutar. Tsarancin TNF suna ɗaure TNF-alpha, suna maida aiki, da kuma tsangwama tare da aikin ƙwaƙwalwar ƙwayar cuta, ta ƙarshe rage lalacewar haɗin gwiwa.
- DMARDs na halitta
- Maganin Halitta Na Halitta: Menene Yake?
Game da Nazarin
Binciken, wanda Dokta Fred Wolfe da Kaleb Michaud ya wallafa, sun yi amfani da asusun ajiyar cututtuka na asibitoci 16,398 marasa lafiya marasa lafiya wanda ba su san ciwon nono ba lokacin da binciken ya fara. An bi marasa lafiya har zuwa shekaru 6.
Binciken bai sami wata ƙungiya mai mahimmanci ba tsakanin ciwon daji da halin yanzu, ko kuma rayuwar RA ta rayuwa, ciki har da nazarin halittu da kuma hanyoyin da ake amfani dasu da kuma maganin corticosteroid . Bugu da ƙari, babu matakan da ke cikin cututtukan cututtuka da ke ciwon nono. Bambanci kawai wanda ke nuna cutar kanjamau a tsakanin marasa lafiya na cututtuka na ƙwayar cuta shine shekaru, tare da mafi girma a tsakanin shekarun 55 zuwa 70. Ba a gano taba shan taba da rubutun jiki ba don zama tsinkaya.
Menene Ciwon ƙwayar Wuta?
Ciwon daji na iya zama mummunar barazanar rai wanda ke farawa cikin kyallen takalma. A cewar ADAM, a cikin rayuwar rayuwa, daya daga cikin mata takwas za a bincikar da ciwon nono. Bangaskiya Addiss ya rubuta a Menene Cutar Cancer? , "Yawancin cututtukan nono suna raguwa da sauri kuma a lokacin da za'a iya jin murya, ana iya girma domin shekaru 5 ko 10.
Maganin nono na farko ba shi da wata alamar cututtuka kuma a baya an sami ciwon ƙwayar cuta, mafi kyawun samun tsira. "
Don Ƙarin Bayani akan Ciwon Kankara:
Mene ne Asusun Bayar da Bayanan Labaran Jama'a na Rheumatic Diseases?
Ƙarin Bayar da Bayani na Ƙasa na Rheumatic (NDB) na kasa da kasa ne na binciken bincike ba tare da riba ba don gudanar da bincike na asibiti na musamman a cututtuka na rheumatic. A halin yanzu NDB yana neman marasa lafiya wanda ke da asali na maganin arthritis , osteoarthritis , fibromyalgia, lupus ko duk wani yanayi na rheumatic.
An tsara bincike na NDB don inganta jiyya da kuma sakamakon wadannan yanayi. NDB tana gudanar da bincike ta hanyar hulɗar kai tsaye tare da marasa lafiya na rheumatology.
Magunguna suna bayar da rahoto a kan duk bangarorin rashin lafiyarsu a cikin tambayoyin kimanin shekara-shekara.
Asusun: Bayar da Bayani na Ƙasa don Rheumatic Diseases, EULAR 2005 Press Release